11. Blood products of human origin and plasma substitutes

11.2. Plasma-derived medicines

11.2.1. Human immunoglobulins

**Anti-tetanus immunoglobulin**

**Indication**: Tetanus

**Medicine type**: Biological agent

**List type**: Core

**Additional notes**: All human plasma-derived medicines should comply with the WHO requirements

**Formulations**: Parenteral > General injections > IM: 500 IU in vial

**EML status history**
- First added in 1984 (TRS 722)
- Changed in 1989 (TRS 796)
- Changed in 1991 (TRS 825)
- Changed in 2003 (TRS 920)
- Changed in 2007 (TRS 950)
- Changed in 2015 (TRS 994)

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Read more about patents.

**Wikipedia**: Anti-tetanus immunoglobulin

**DrugBank**: Anti-tetanus immunoglobulin (Tetanus Immune Globulin)

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended that immunoglobulins of human origin currently listed in Section 19.2 Sera and immunoglobulins, should be transferred to Section 11.2.1 Human immunoglobulins.